High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed prostate cancer on transrectal ultrasound or transperineal template prostate biopsies meeting the following criteria:
• * Stage ≤ T3b, N0, M0 disease
• * Gleason score ≤ 8
• * Serum PSA ≤ 20 ng/mL
• * No metastatic disease and nodal spread by staging CT or MRI
• * Negative bone scan within the past 6 months
• Index lesion or other secondary lesions with a volume of ≥ 0.5 cc by MRI
• * Secondary lesions are included in the treatment provided ≥ 1 neurovascular bundle and 40-50% of prostatic tissue can be preserved
• PATIENT CHARACTERISTICS:
• Able to tolerate a transrectal ultrasound
• Able to undergo major surgery as assessed by a consultant anesthesiologist
• Able to undergo MRI scanning (i.e., no severe claustrophobia, permanent cardiac pacemaker, metallic implant)
• No urethral stricture or presence of metal implants or stents in the urethra
• No prostatic calcification or cysts (on transrectal ultrasound) that would interfere with effective delivery of HIFU therapy
• No allergy to latex
• PRIOR CONCURRENT THERAPY:
• No prior radiotherapy
• No prior treatment with any of the following:
• * Transurethral resection of the prostate or equivalent procedures within the past 2 years
• * High-intensity focused ultrasound ablation (HIFU)
• * Cryosurgery
• * Thermal or microwave therapy to the prostate
• No prior significant rectal surgery that prevents insertion of the transrectal HIFU probe
• More than 12 months since prior androgen suppression or hormone treatment for prostate cancer